Equities research analysts predict that Vical Incorporated (NASDAQ:VICL) will post earnings per share of ($0.22) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Vical’s earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.21). Vical posted earnings of ($0.27) per share in the same quarter last year, which indicates a positive year over year growth rate of 18.5%. The business is expected to report its next quarterly earnings results on Monday, October 22nd.

On average, analysts expect that Vical will report full year earnings of ($0.95) per share for the current year, with EPS estimates ranging from ($0.97) to ($0.92). For the next year, analysts expect that the firm will report earnings of ($1.02) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Vical.

Vical (NASDAQ:VICL) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. Vical had a negative net margin of 207.71% and a negative return on equity of 33.70%. The business had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.51 million.

A number of research analysts have weighed in on VICL shares. Zacks Investment Research upgraded shares of Vical from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Friday, August 10th. HC Wainwright set a $4.00 price objective on shares of Vical and gave the company a “buy” rating in a research report on Wednesday, August 8th.

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in Vical during the second quarter valued at $205,000. BlackRock Inc. increased its position in Vical by 20.0% during the second quarter. BlackRock Inc. now owns 394,320 shares of the biotechnology company’s stock valued at $453,000 after acquiring an additional 65,732 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Vical by 13.9% during the second quarter. Renaissance Technologies LLC now owns 877,729 shares of the biotechnology company’s stock valued at $1,009,000 after acquiring an additional 107,100 shares during the last quarter. Institutional investors and hedge funds own 45.78% of the company’s stock.

VICL stock opened at $1.28 on Wednesday. Vical has a twelve month low of $1.02 and a twelve month high of $2.89. The firm has a market cap of $29.89 million, a price-to-earnings ratio of -1.27 and a beta of 0.64.

About Vical

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.

Recommended Story: S&P 500 Index

Get a free copy of the Zacks research report on Vical (VICL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.